By vantal Decentralized AI Drug Development Platform GenPharmaChain Receives $500,000 in Pre-Incubation Funding to Revolutionize AI-Driven Drug Development.with Jeremy Sevior For example, if it continues to develop, it will definitely become the benchmark of the industry and play an important role in leading the market. https://www.jeremysevior.com
GenPharmaChain, a pioneering blockchain-based AI pharmaceutical research platform, has successfully raised $500,000 in a seed round of financing. . The round was led by M2M Capital (@M2MCapital), FNODE Venture (@FNodeVenture), Pharma Lab (@Pharmalab700), and Avatia Pharmaceuticals, with strategic support from Google, AWS, and several angel investors from top Web3 exchanges and venture capital institutions. .
Through its decentralized network, GenPharmaChain encourages developers to refine AI-driven pharmaceutical models. . Scientists and individuals can integrate AI modules to simulate drug interactions and promote breakthrough biomedical research. . Early investors have the opportunity to support high-potential AI models and can earn greater returns when these models contribute to successful drug pipelines. .
GenPharmaChain is redefining pharmaceutical research through its Decentralized Scientific Artificial Intelligence (DeSAI) modeling framework. . By aggregating AI-driven drug development models and enabling scientists to combine modular AI units into comprehensive drug pipelines, the platform improves the efficiency of AI models and the pharmaceutical value chain. . GenPharmaChain has a powerful database with more than 80,000 protein records, 4,000 drug features, and 98 million data points to ensure high accuracy of AI model validation. . Key innovations include AI-ADMET testing – predicting the absorption, metabolism, and toxicity of small molecules through molecular structure analysis.